Actively Recruiting
Partial Liver Segment 2/3 Transplantation Study
Led by Oslo University Hospital · Updated on 2024-02-06
20
Participants Needed
1
Research Sites
730 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The patients will receive hepatectomy as a 2 stage procedure. In the first surgical procedure liver segments 2-3 are removed and liver donor segments 2-3 inserted. After growth of donor segments 2-3, the remaining liver segments of the recipient are removed. The patient will at this time have only donor liver tissue in place.
CONDITIONS
Official Title
Partial Liver Segment 2/3 Transplantation Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically verified adenocarcinoma in colon or rectum
- Liver metastases not suitable for liver resection
- No signs of extra hepatic metastatic disease or local recurrence on PET/CT within 4 weeks prior to transplant unit faculty meeting, except 1-3 resectable lung lesions all under 15mm
- No signs of extra hepatic metastatic disease on CT thorax/abdomen/pelvis within 4 weeks prior to transplant unit faculty meeting, except 1-3 resectable lung lesions all under 15mm
- No local recurrence on MR-pelvis scan within 4 weeks prior to transplant unit faculty meeting for rectal cancer patients
- No signs of local recurrence by colonoscopy or CT colography within 12 months prior to transplant unit faculty meeting
- Good performance status, ECOG 0 or 1
- Satisfactory blood tests: Hb over 10g/dl, neutrophils over 1.0 (after any G-CSF), platelets over 75, bilirubin less than 2 times upper normal, ASAT and ALAT less than 5 times upper normal, creatinine less than 1.25 times upper normal, albumin above lower normal
- Signed informed consent and expected cooperation for treatment and follow-up
- Received at least 8 weeks of chemotherapy
You will not qualify if you...
- Weight loss over 10% in the last 6 months
- Body mass index (BMI) over 30
- Previously diagnosed bone or central nervous system metastatic disease
- Previously diagnosed breast cancer or malignant melanoma
- Palliative resection of primary colorectal cancer tumor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Oslo University Hospital
Oslo, Norway, 0424 Oslo
Actively Recruiting
Research Team
M
Magnus Smedman, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here